Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

Inclusion Criteria:

• Signed informed consent must be obtained prior to participation in the study

• Male or female patients ≥ 50 years of age at screening who are treatment naive

• Active choroidal neovascularization (CNV) secondary to AMD that affects the centralsubfield, including retinal angiomatous proliferation (RAP) with a CNV component,confirmed by presence of active leakage from CNV seen by fluorescein angiography andsequellae of CNV, e.g. pigment epithelial detachment (PED), subretinal orsub-retinal pigment epithelium (sub-RPE) hemorrhage, blocked fluorescence, macularedema (study eye)

• Presence of intraretinal fluid (IRF) or subretinal fluid (SRF) that affects thecentral subfield, as seen by Spectral Domain Optical Coherence Tomography (SD-OCT) (study eye)

• Best-corrected visual acuity (BCVA) score between 83 and 38 letters, inclusive,using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testingcharts at both screening and baseline visit (study eye)

Exclusion Criteria:

• Ocular conditions/disorders at screening or baseline which could, in the opinion ofthe investigator, prevent response to study treatment or may confound interpretationof study results, compromise visual acuity or require planned medical or surgicalintervention during the first 12-month study period, structural damage of the fovea,atrophy or fibrosis at the center of the fovea (study eye)

• Any active intraocular or periocular infection or active intraocular inflammation,at screening or baseline (study eye)

• Uncontrolled glaucoma defined as intraocular pressure (IOP) > 25 mmHg on medication,or according to investigator's judgment, at screening or baseline (study eye)

• Ocular treatments: previous treatment with any anti-vascular endothelial growthfactor (VEGF) drugs or investigational drugs, intraocular or periocular steroids,macular laser photocoagulation, photodynamic therapy, vitreoretinal surgery,intraocular surgery (study eye)

• Stroke or myocardial infarction during the 6-month period prior to baseline

• Systemic anti-VEGF therapy at any time.